Australia's largest pharmaceutical company has brushed off investor concerns after Donald Trump announced massive tariffs on medicines shipped to the United States.

It remains unclear whether CSL would be directly impacted by the US president's proposed 100 per cent tariffs, which he announced in a post on social media.

CSL, Australia's seventh-largest public firm by market capitalisation, makes up the bulk of Australia's $2.2 billion pharmaceutical export trade to the US.

The ASX blue-chip stock's main exports to the US are medicines derived from blood plasma manufactured at its plant in Melbourne.

The firm also has a substantial footprint in the US, where it employs 19,000 staff, or about two thirds of its overseas workforce.

Health Minister Mark Butler said the government was still

See Full Page